News GSK closes on approval of asthma hope depemokimab GSK is poised for the first major approval of depemokimab, a long-acting drug for severe asthma that can be dosed just twice a year.
News AZ, Organon fall foul of UK's code on pharma promotion AstraZeneca and Organon have breached the UK pharma industry's code of practice with promotions for an asthma drug and a contraceptive implant.
News Trials set up filings for AZ's triple therapy in asthma AstraZeneca's three-drug inhaler Breztri has shown efficacy for uncontrolled asthma in a pair of trials that could extend its label beyond COPD.
News Sanofi's 'daughter of Dupixent' heads to phase 3 in asthma Sanofi is preparing a phase 3 programme for asthma candidate amlitelimab, despite mixed data in a phase 2 trial.
News Stopwatch starts on reviews of GSK's long-acting asthma drug Regulators have started reviews of GSK's depemokimab, aiming to become the first drug for asthma that can be dosed twice a year.
News Study finds AZ's benralizumab a 'game-changer' in asthma Researchers in the UK say that AstraZeneca's benralizumab can have a dramatic impact if it was used to treat acute asthma attacks
News Kyverna rises on stiff person syndrome data Kyverna hopes to file CAR-T therapy miv-cell for approval as the first therapy for stiff person syndrome, a rare and debilitating autoimmune disease.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
